Mitochondrial Dysfunction and Neuronal Metabolism in Neurodegenerative Diseases: Understanding the Link between Energy Deficits and Pathogenesis

Emily Longe*

Department of Neurology, University of Cambridge, Cambridge, UK

Commentary

Received: 26-Dec-2024, Manuscript No. Neuroscience-24-156707 **Editor assigned:** 31-Dec-2024, Pre QC No. Neuroscience-24-156707 (PQ); **Reviewed:** 14-Jan-2025, QC No. Neuroscience-24-156707; **Revised:** 09-Mar-2026, Manuscript No. Neuroscience-24-156707 (R); **Published:** 16-Mar-2026, DOI: 10.4172/rrns.10.002

***For Correspondence:** Emily Longe, Department of Neurology University of Cambridge, Cambridge, UK; **E-mail:** emily.longe@cam.ac.uk

Citation: Longe E. Mitochondrial Dysfunction and Neuronal Metabolism in Neurodegenerative Diseases: Understanding the Link between Energy Deficits and Pathogenesis. RRJ Neuroscience. 2026;10:002.

DESCRIPTION

Mitochondria, the cellular powerhouses, are integral to energy production, specifically through Oxidative Phosphorylation (OXPHOS), which generates ATP. ATP is essential for the proper functioning of neurons, especially given their high energy demands. In recent years, research has unveiled a growing connection between mitochondrial dysfunction, impaired neuronal metabolism, and the onset of Neurodegenerative Diseases (NDs), including Alzheimer's Disease (AD), Parkinson's Disease (PD), and Huntington's Disease (HD). This article explores how mitochondrial dysfunction and energy deficits contribute to the pathogenesis of these disorders, focusing on the molecular mechanisms, potential biomarkers, and therapeutic targets.

Mitochondrial dysfunction and neurodegeneration

Mitochondrial dysfunction is a hallmark of many NDs. Neurons rely on mitochondrial ATP production to sustain cellular processes such as ion gradients, neurotransmitter recycling, and synaptic transmission. Mitochondria also play key roles in apoptosis, calcium buffering, and redox balance. In neurodegenerative diseases, mitochondrial function is compromised, leading to a cascade of cellular events that exacerbate neuronal damage.

In AD, mitochondrial dysfunction is linked to the accumulation of amyloid-beta (Aβ) plaques and tau tangles, which impair the mitochondrial Electron Transport Chain (ETC). The resulting decrease in ATP production further exacerbates the energy deficit in neurons, contributing to synaptic failure and cognitive decline. In PD, mutations in genes such as PARKIN and PINK1 affect mitochondrial quality control mechanisms, leading to the accumulation of damaged mitochondria, which, in turn, disrupts cellular metabolism.

Energy deficits and neuronal metabolism

In neurodegenerative diseases, mitochondrial dysfunction leads to significant alterations in neuronal metabolism. One of the primary metabolic changes is the shift from oxidative phosphorylation to anaerobic glycolysis. This shift results in reduced ATP production and an increase in lactate accumulation, which can lead to a toxic environment within the brain. Neurons, especially in regions such as the hippocampus and substantia nigra, become more susceptible to excitotoxicity, oxidative stress, and inflammation.

Mechanisms underlying mitochondrial dysfunction in neurodegeneration

At the molecular level, mitochondrial dysfunction in neurodegenerative diseases can arise from genetic mutations, oxidative stress, and environmental factors. Mutations in mitochondrial DNA (mtDNA) or nuclear genes that encode mitochondrial proteins lead to defective mitochondrial respiratory complexes and compromised ATP production. For example, in HD, the expansion of CAG repeats in the HTT gene produces the mutant huntingtin protein, which impairs mitochondrial trafficking and function. Oxidative stress, a byproduct of impaired mitochondrial activity, further damages cellular components, including proteins, lipids, and DNA. This oxidative damage creates a vicious cycle that accelerates neuronal death.

Therapeutic implications and biomarkers

Targeting mitochondrial dysfunction presents a promising therapeutic strategy for neurodegenerative diseases. Strategies that enhance mitochondrial biogenesis, improve mitochondrial dynamics, or modulate mitochondrial-autophagy (mitophagy) are being explored. For example, compounds like coenzyme Q10, creatine, and PPAR-gamma agonists have shown some potential in preclinical models by restoring mitochondrial function and improving neuronal metabolism. Biomarkers related to mitochondrial dysfunction, such as mitochondrial DNA damage, ATP levels, and mitochondrial protein markers, are emerging as diagnostic tools for early-stage neurodegeneration.

CONCLUSION

Mitochondrial dysfunction and energy deficits are central to the pathogenesis of neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's disease. The disruption of mitochondrial function leads to a cascade of metabolic alterations, including decreased ATP production, increased oxidative stress, and impaired neuronal signaling. These disturbances not only contribute to the progression of neurodegeneration but also serve as potential targets for therapeutic intervention. Understanding the link between mitochondrial dysfunction and neuronal metabolism is key to developing effective treatments for these conditions. Future research into mitochondrial biology and energy metabolism could lead to new therapies that restore mitochondrial function, slow disease progression, and enhance the quality of life for neurodegenerative disease patients.